# A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

> **NCT03595657** · PHASE2 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Extranodal Natural Killer/T-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CS1001

## Key facts

- **NCT ID:** NCT03595657
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-12
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595657, "A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03595657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*